BDTX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 16, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Black Diamond Therapeutics Reports Q2 2026 Financial Results and Silevertinib Clinical Progress

Aug 5, 2026

8-K

Black Diamond Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 29, 2026

8-K

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 21, 2026

8-K

Black Diamond Therapeutics Reports Q1 2026 Financial Results and Clinical Progress for Silevertinib

May 7, 2026

8-K

Black Diamond Therapeutics Reports 2025 Financial Results and Clinical Progress for Silevertinib

Mar 16, 2026

8-K

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for Phase 2 GBM Trial; ORR 60% and CNS ORR 86% in 43 patien

Dec 3, 2025

Prospectus

TYPE

HEADLINE

FILED AT

424B5

SHELF OFFERING | Shares amount: 15,000,000 | Share price: $5.00 | Offering amount: $75,000,000.00

Jun 30, 2023

424B5

SHELF OFFERING | Share price: $5.73 | Offering amount: $75,000,000.00

Jun 29, 2023

424B4

OFFERING | Shares amount: 10,586,316 | Share price: $19.00 | Offering amount: $201,140,004.00

Jan 30, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 16, 2026

S-3

November 2025 SHELF and ATM

Nov 13, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 6, 2025

S-8

Registration

Mar 12, 2024

S-8

Registration

Mar 9, 2023

S-3

SHELF | ATM | Offering amount: $500,000,000.00 | Float: 22,681,495 | Amount sold to date: $0.00 EFFECTIVE

Nov 14, 2022

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 18, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 18, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

Black Diamond Therapeutics, Inc. BDTX · SEC Filings